Kristen Fortney, CEO of BioAge, and Vijay Pande, founding partner at Andreessen Horowitz's Bio + Health division, delve into the fascinating biology of aging. They discuss Kristen's inspiring journey from math to founding a company focused on health and longevity. The duo highlights the challenges of translating research from mouse models to human therapeutics. They also explore innovative interventions to enhance healthspan versus lifespan, touching on societal implications and future prospects in aging research.

with @LauraDeming, @kpfortney, @vijaypande, and @omnivorousread Welcome to the first episode of Bio Eats World, a brand new podcast all about how biology is technology. Bio is breaking out of the lab and clinic and into our daily lives—on the verge of revolutionizing our world in ways we are only just beginning to imagine. In this episode, we talk all about the science of aging. Once a fringe field, aging research is now entering a new phase with the first clinical trials of aging-related drugs. As the entire field shifts into this moment of translation, what have we learned? What are the basic approaches to developing aging-related drugs? How is studying aging helping us understand diseases like cancer and Alzheimer's—and increasing the amount of time we are healthy—today?  In this conversation, Laura Deming, founder of The Longevity Fund; Kristen Fortney, co-founder of BioAge, a clinical-stage company focused on finding drugs to extend healthspan; Vijay Pande, general partner at a16z; and host Hanne Winarsky discuss the entire arc of aging science from one genetic tweak in a tiny worm to changing a whole paradigm of healthcare delivery.

Kristen Fortney, co-founder of BioAge, dives into the revolutionary science of aging and healthspan. The conversation covers groundbreaking research on aging-related drugs and their potential to transform healthcare. They explore how insights from aging can reshape our understanding of diseases like Alzheimer’s and cancer. The group discusses innovative therapies, the significance of biomarkers, and the importance of diverse founders in the longevity sector. Fortney's insights highlight a new era where biology meets technology, paving the way for a healthier future.

Join an enlightening discussion with Kristen Fortney, CEO of BioAge Labs, Jeff Kaditz, co-founder of Q.Bio, David Sinclair, co-director at Harvard's Glenn Center, and Michael Snyder, Stanford's Genetics Chair. They dive into groundbreaking advancements in longevity, highlighting the importance of early disease detection and genomics. Explore innovative tools targeting aging, like the elimination of senescent cells, and how tech is revolutionizing healthcare from reactive to proactive. Discover the societal shifts towards personalized health data ownership for improved aging outcomes.

In this engaging discussion, Kristen Fortney, CEO of BioAge and expert in anti-aging therapies, explores the frontier of geroscience alongside Dr. Thomas Rando from Stanford. They delve into the fascinating concepts of increasing 'health span' over just longevity. The conversation uncovers groundbreaking treatments like young blood transfusions and senolytics, as well as innovative methods harnessing genomics and technology. They also examine the societal changes needed to embrace these therapies and the potential medical revolution on aging.